Screener
Corvus Pharmaceuticals CRVS Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-057100
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Current liabilities: | ||
| Accounts payable | $4,697 | $2,491 |
| Operating lease liability | 428 | 403 |
| Accrued and other liabilities | 6,985 | 6,486 |
| Total current liabilities | 12,110 | 9,380 |
| Operating lease liability | 406 | 534 |
| Total liabilities | 12,516 | 9,914 |
| Commitments and contingencies (Note 15) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Corvus Pharmaceuticals's accrued expenses?
- Corvus Pharmaceuticals (CRVS) reported accrued expenses of $6.99M in Q1 2026.
- How has Corvus Pharmaceuticals's accrued expenses changed year-over-year?
- Corvus Pharmaceuticals's accrued expenses increased by 80.4% year-over-year, from $3.87M to $6.99M.
- What is the long-term trend for Corvus Pharmaceuticals's accrued expenses?
- Over 2 years (2023 to 2025), Corvus Pharmaceuticals's accrued expenses has grown at a 27.8% compound annual growth rate (CAGR), from $3.97M to $6.49M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Corvus Pharmaceuticals's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude